• Liminatus Pharma held its 2026 annual shareholder meeting on Aug. 3, 2026.
• Shareholders ratified Withum Smith+Brown PC as independent registered public accounting firm for fiscal 2026.
• Investors authorized the board to pursue a reverse stock split of up to 1-for-50.
• The charter amendment tied to the reverse split authorization was also adopted.
• The reverse split ratio, timing, and execution remain at the board’s discretion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-090423), on August 04, 2026, and is solely responsible for the information contained therein.